Hey there! Welcome!
Get updated on
ERS 2026_CH web banner-01
ERS 2026_CH web banner-02
ERS 2026_CH web banner-02
Top Picks

calendar
13 Nov, 26
dot
link
AHA 2026
The sessions presented at AHA 2026, underscore the importance of secondary prevention in MI patients and focus on the benefits of beta-blocker treatment and reperfusion treatment in these patients.

calendar
12 Nov, 26
dot
link
AHA 2026
The AHA highlights focus on risk-guided intensive BP control, novel aldosterone synthase inhibitors, GLP-1RA–mediated BP reduction, digital BP management, and real-world combination therapy outcomes.

calendar
16 Nov, 26
dot
link
BMC Pedia
  • Using hemoglobin and serum ferritin , normal iron status was observed in 82-90% of infants during the first year.
  • Iron deficiency prevalence increased from 5.6-11.5% (Hb+SF) to 20.2-27.7% when zinc protoporphyrin (ZnPP) was included.
  • Anemia affected 4.5-7.7% of infants; >50% of cases were non-iron deficiency anemia (non-IDA), and biomarker agreement was low.

calendar
9 Nov, 26
dot
link
BMC Infect. Dis.
  • Meta-analysis of 99 cohort studies found poor glycemic control significantly reduced treatment success (adjusted OR 0.22) & sputum conversion (adjusted OR 0.28).
  • Poor glycemic control was associated with lower lesion resolution and cavity closure.
  • Recurrence risk was nearly 5-fold higher with poor glycemic control; no significant differences were observed between FBG and HbA1c for short-term outcomes.

calendar
6 Nov, 26
dot
link
EP Europace.
  • Among 2,712 Swiss-AF participants (mean age 73 yrs; 30.8% female), MRI-detected brain infarcts increased from 22.8% (AF-/HF-) to 44.6% (AF+/HF+), while white matter hyperintensities (WMH) increased from 43.2% to 65.6%
  • AF & HF were independently associated with brain infarcts (AF: OR 1.78; HF: OR 1.32; both p<0.001) & WMH (AF: OR 1.71; HF: OR 1.45; both p<0.001), with no significant AF-HF interaction.

calendar
5 Nov, 26
dot
link
Diabetes Obes Metab.
  • In a cohort of obesity-medication eligible adults without diabetes, 12 mo of persistent tirzepatide treatment produced clinically meaningful weight loss in both GLP-1 RA–naïve & experienced patients
  • Mean weight reduction was 19.3% in GLP-1 RA–naïve patients & 13.1% in GLP-1 RA–experienced patients
  • >85% had ≥1 obesity-related comorbidity at baseline, supporting effectiveness comparable to clinical trial outcomes.